Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nurexone Biologic Inc (NRX.VN)

Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 40,138
  • Shares Outstanding, K 67,489
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,639 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.37
Trade NRX.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.02 on 08/27/24
  • Next Earnings Date 11/22/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.550 +3.64%
on 09/26/24
0.650 -12.31%
on 09/16/24
+0.010 (+1.79%)
since 09/11/24
3-Month
0.520 +9.62%
on 08/14/24
0.740 -22.97%
on 07/18/24
-0.070 (-10.94%)
since 07/11/24
52-Week
0.255 +123.53%
on 11/02/23
1.190 -52.10%
on 02/20/24
+0.310 (+119.23%)
since 10/11/23

Most Recent Stories

More News
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...

SNY : 54.96 (+0.35%)
TAK : 14.30 (-0.07%)
NRX.VN : 0.570 (-1.72%)
BMY : 52.20 (-0.38%)
NRX : 0.14 (+7.69%)
When Technicals and Fundamentals Converge, A Nice Uptrend Ensues

Some investors only pay attention to fundamentals. Others put more weight on technical charts. Another way of looking at it is to think of technical as being useful for quick decisions for those good at...

RIO : 67.23 (+0.58%)
NRDS : 11.98 (+6.49%)
NOA.TO : 26.12 (+1.08%)
NRX.VN : 0.570 (-1.72%)
NOA : 18.94 (+0.85%)
NRX : 0.14 (+7.69%)
24 Cent Micro Cap May Hold The Key To Potential Breakthrough In Acute Spinal Cord Injury

An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined...

TECH : 73.36 (+0.52%)
LLY : 932.06 (+2.35%)
CAPR : 17.77 (+3.68%)
NRX.VN : 0.570 (-1.72%)
NRX : 0.14 (+7.69%)
PARS : 0.0200 (-48.72%)
NurExone Announces Appointment of New Director and Provides Corporate Updates

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July...

NRX.VN : 0.570 (-1.72%)
NurExone Engages Investor Relations Service Provider

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided...

NRX.VN : 0.570 (-1.72%)
NurExone Announces Equity Incentive Plan Grants and Director Resignation

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided...

NRX.VN : 0.570 (-1.72%)
United States Patent Office Allows Patent to Exosome Biomedical Company NurExone

The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System diseaseHaifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic...

NRX.VN : 0.570 (-1.72%)
NurExone Biologic Inc Named an Emerging Leader in Exosome-Based Treatment of Spinal Cord Injury

Background Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI...

NRX.VN : 0.570 (-1.72%)
NurExone Biologic Inc. Opens the Market

/CNW/ - Representatives from NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) and their team joined Yossi Boker, TMX Head of Business...

NRX.VN : 0.570 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly,...

See More

Key Turning Points

3rd Resistance Point 0.570
2nd Resistance Point 0.570
1st Resistance Point 0.570
Last Price 0.570
1st Support Level 0.570
2nd Support Level 0.570
3rd Support Level 0.570

See More

52-Week High 1.190
Fibonacci 61.8% 0.833
Fibonacci 50% 0.723
Fibonacci 38.2% 0.612
Last Price 0.570
52-Week Low 0.255

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar